XBiotech(US:XBIT) Prnewswire·2024-12-27 21:20Core Viewpoint - The investigation into XBiotech Inc. involves allegations of securities fraud and unlawful business practices by the company and its officers or directors [1]. Company Summary - XBiotech announced on December 23, 2024, that it is pausing its phase 2 rheumatoid arthritis program due to the candidate, Natrunix, failing to meet its primary endpoint, citing "substantial irregularities that make unequivocal interpretation of the findings difficult" [6]. - Following this announcement, XBiotech's stock price experienced a significant decline during intraday trading on the same day [2]. Legal Context - Pomerantz LLP is investigating claims on behalf of investors of XBiotech, encouraging affected investors to reach out for potential class action participation [4]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [5].